Background
Materials and methods
Regional ventilation and perfusion measured by EIT
-
Both ventilation and perfusion maps were divided into symmetrical, non-overlapping, four cross-quadrants: lower left (LL), lower right (LR), upper left (UL) and upper right (UR). Only the ventilated or perfused regions were evaluated. The regional ventilation distribution (%), perfusion distribution (%) and V/Q (%) were calculated in each quadrant (LL, LR, UL and UR).
-
Distribution defects of each quadrant were scored as follows: 0 (quadrant distribution% ≥ 15%), 1 (15% > quadrant distribution% ≥ 10%) and 2 (quadrant distribution% < 10%). The quadrant distribution defect scores ranged from 0 (minimal) to 2 (maximal). The cutoff value of 15% was derived from the lowest 5th percentile of the quadrant distribution in the control group (including quadrant ventilation and perfusion distributions). Further ranges (between 10 and 15%, lower than 10%) were selected considering clinical simplicity and the frequency of ventilation and perfusion occurrence in all 744 quadrants in the study population of patients with ARF. The 5% ranges of these three score ranks were derived from the 50% gradient quadrants’ distributions from 5 to 25th percentile.
-
DefectV, and DefectQ scores were calculated by the sum of four cross-quadrants to denote the corresponding defect scores for ventilation and perfusion, respectively. DefectV+Q was the combined score calculated as DefectV + DefectQ.
Statistical analysis
Results
Comparisons of different groups
Variables | Control group n = 15 | PED group n = 14 | DLD group n = 21 | FLD group n = 58 | ANOVA-P value (Kruskal–Wallis test) |
---|---|---|---|---|---|
Age (years) | 54 ± 14 | 59 (52, 68) | 67 (55, 71) | 65 (54, 75) | 0.083 |
Sex (female/male) | 6/9 | 10/4 | 9/12 | 21/37 | N/A |
APACHE II score | 14 ± 5 | 15 (10, 17) | 20 (15, 28)a, b | 18 (14, 25)a, b | 0.01 |
HR (bpm) | 78 (65, 93) | 87 (78, 93) | 85 (80, 97) | 94 (84, 103)a | 0.019 |
MAP (mmHg) | 87 ± 9 | 85 ± 10 | 84 ± 9 | 83 ± 12 | 0.336 |
FiO2 (%) | 30 (30, 35) | 45 (40, 80)a | 40 (33, 58)a | 40 (35, 75)a | < 0.0001 |
PaO2/FiO2 (mmHg) | 390 (347, 474) | 156 (86, 209)a | 210 (117, 244)a | 236 (170, 290)a, b | < 0.0001 |
d-Dimer (mg/L FEU) | 1.0 (0.5, 3.0) | 4.1 (2.7, 4.9) | 4.6 (1.6, 6.2) | 5.5 (1.9, 12.4)a | 0.014 |
NE dose (μg/kg min) | 0.00 (0.00, 0.09) | 0.08 (0.00, 0.39)a | 0.02 (0.00, 0.23) | 0.08 (0.00, 0.26) | 0.237 |
28-day mortality | 0/15 | 4/14 | 3/21 | 11/58 | N/A |
Variables | Control group n = 15 | PED group n = 14 | DLD group n = 21 | FLD group n = 58 | ANOVA-P value (Kruskal–Wallis test) |
---|---|---|---|---|---|
UR-ventilation (%) | 31 ± 7 | 25 (16, 37) | 29 (24, 34) | 36 (23, 44) | 0.088 |
UL-ventilation (%) | 29 ± 9 | 24 (15, 33) | 23 (19, 29) | 28 (19, 39)b | 0.206 |
LR-ventilation (%) | 22 ± 10 | 23 (19, 31) | 23 (19, 29) | 18 (10, 26) | 0.041 |
LL-ventilation (%) | 17 ± 6 | 28 (19, 30) | 22 (16, 25) | 18 (8, 25)b | 0.010 |
UR-perfusion (%) | 24 (19, 30) | 20 (9, 34) | 23 ± 6 | 26 ± 11 | 0.271 |
UL-perfusion (%) | 27 ± 5 | 22 (17, 27) | 26 (21, 30) | 27 (21, 33) | 0.200 |
LR-perfusion (%) | 22 (21, 27) | 18 (8, 30) | 25 (21, 29) | 21 (15, 27) | 0.147 |
LL-perfusion (%) | 22 (21, 30) | 37 (26, 42) | 22 (19, 27) | 22 (17, 29)b | 0.015 |
UR-V/Q (%) | 1.3 (1.1, 1.5) | 1.3 (0.9, 1.7) | 1.2 (1.0, 1.5) | 1.2 (1, 1.7) | 0.978 |
UL-V/Q (%) | 1.1 (0.8, 1.3) | 0.9 (0.5, 1.8) | 1.0 (0.7, 1.2) | 1.1 (0.8, 1.3) | 0.795 |
LR-V/Q (%) | 0.9 (0.7, 1.1) | 1.5 (1.0, 2.6) | 1.1 (0.9, 1.2) | 0.8 (0.6, 1.1)b | 0.09 |
LL-V/Q (%) | 0.6 (0.7, 0.8) | 0.8 (0.6, 1.0) | 0.7 (0.7, 1.1) | 0.7 (0.4, 1.0) | 0.250 |
VQ Match% | 72 (65, 80) | 51 (36, 58)a | 66 (62, 75)b | 63 (47, 73)a | < 0.0001 |
DeadSpace% | 12 (7, 17) | 40 (30, 54)a | 18 (14, 27)b | 14 (8, 23)b | < 0.0001 |
Shunt% | 12 (8, 19) | 9 (5, 12) | 13 (5, 20) | 20 (8, 33)b | 0.015 |
DefectV score | 0 (0, 1) | 1 (0, 1) | 0 (0, 0.5) | 2 (1, 3)a, b, c | < 0.0001 |
DefectQ score | 0 (0, 0) | 1 (1, 2)a | 0 (0, 0)b | 0 (0, 1)a, b, c | < 0.0001 |
DefectV+Q score | 0 (0, 1) | 2.5 (2, 4)a | 0 (0, 1)b | 3 (1, 4)a, c | < 0.0001 |
Correlation between PaO2/FiO2 and EIT-parameters
Diagnostic ability of EIT parameters for determining the three preset etiologies (PED, DLD and FLD) in ARF patients
Items | Parameters used | ROC area | 95% CI | Cutoff value | Sensitivity (%) | Specificity (%) |
---|---|---|---|---|---|---|
Identification of PED (14/93 PED) | DeadSpace% | 0.894a | 0.821–0.945 | > 30.37% | 78.6 | 92.4 |
DefectQ score | 0.787a | 0.672–0.902 | > 3.5 | 21.4 | 100 | |
VQ Match% | 0.752a | 0.624–0.885 | < 36.6% | 35.7 | 96.2 | |
Shunt% | 0.697a | 0.575–0.819 | < 3.23% | 7.1 | 91.1 | |
LR-V/Q (%) | 0.750a | 0.577–0.923 | > 1.72 | 50 | 94.9 | |
d-Dimer (mg/L FEU) | 0.457 | 0.328–0.586 | > 6.1 | 14.3 | 60.8 | |
Identification of DLD (21/93 DLD) | DefectV score | 0.837 | 0.754–0.920 | < 0.5 | 76.2 | 79.2 |
DefectQ score | 0.726 | 0.621–0.832 | < 0.5 | 85.7 | 55.6 | |
DefectV+Q score | 0.893 | 0.828–0.959 | < 0.5 | 66.7 | 90.3 | |
Identification of FLD (58/93 FLD) | DefectV score | 0.832 | 0.750–0.915 | > 2.5 | 39.7 | 97.1 |
DefectV+Q score | 0.745 | 0.644–0.846 | > 4.5 | 20.7 | 97.1 | |
Shunt% | 0.674 | 0.565–0.783 | > 29.3% | 34.5 | 91.4 | |
DeadSpace% | 0.728 | 0.621–0.835 | < 7.9% | 25.9 | 91.4 |